

18-Month study of intravenous immunoglobulin for tre

Neurobiology of Aging

30, 1728-1736

DOI: [10.1016/j.neurobiolaging.2007.12.021](https://doi.org/10.1016/j.neurobiolaging.2007.12.021)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Amyloid- β immunisation for Alzheimer's disease. <i>Lancet Neurology</i> , The, 2008, 7, 805-811.	4.9	149
3	Passive immunotherapies for Alzheimer's disease. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2008, 5, 185-189.	0.5	0
4	Clinical immunotherapy trials in Alzheimer's disease. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2008, 5, 177-183.	0.5	4
5	Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2008, 1782, 549-558.	1.8	72
6	Preventing Alzheimer's Disease. <i>CNS Drugs</i> , 2008, 22, 887-902.	2.7	16
7	Review: New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins. <i>Therapeutic Advances in Neurological Disorders</i> , 2008, 1, 115-124.	1.5	5
8	Amyloid β -Protein Assembly as a Therapeutic Target of Alzheimer's Disease. <i>Current Pharmaceutical Design</i> , 2008, 14, 3231-3246.	0.9	107
9	Immunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies. <i>Journal of Alzheimer's Disease</i> , 2008, 15, 157-168.	1.2	107
10	Diminished Amyloid- β Burden in Tg2576 Mice Following a Prophylactic Oral Immunization with a Salmonella-Based Amyloid- β Derivative Vaccine. <i>Journal of Alzheimer's Disease</i> , 2009, 18, 961-972.	1.2	20
11	Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 12145-12150.	3.3	171
12	Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of A β oligomers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 1971-1976.	3.3	592
13	Is passive immunization for Alzheimer's disease "alive and well" or "dead and buried"? <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 481-491.	1.4	28
14	Activation of cryptic IgG reactive with BAFF, amyloid beta peptide and GM-CSF during the industrial fractionation of human plasma into therapeutic intravenous immunoglobulins. <i>Clinical Immunology</i> , 2009, 133, 52-60.	1.4	20
15	An update on treatment and prevention strategies for Alzheimer's disease. <i>Current Neurology and Neuroscience Reports</i> , 2009, 9, 368-376.	2.0	39
16	Pharmaceutical treatment for cognitive deficits in Alzheimer's disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps. <i>Psychopharmacology</i> , 2009, 202, 15-36.	1.5	31
17	Clinical applications of intravenous immunoglobulins in neurology. <i>Clinical and Experimental Immunology</i> , 2009, 158, 34-42.	1.1	67
18	Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. <i>Neuroscience</i> , 2009, 158, 1074-1089.	1.1	110
19	Immune therapy for age-related diseases. <i>Trends in Immunology</i> , 2009, 30, 344-350.	2.9	33

#	ARTICLE	IF	CITATIONS
20	Drug development for Alzheimer's disease: Where are we now and where are we headed?. American Journal of Geriatric Pharmacotherapy, 2009, 7, 167-185.	3.0	124
22	Beyond the neurotransmitter-focused approach in treating Alzheimer's Disease: drugs targeting β -amyloid and tau protein. Aging Clinical and Experimental Research, 2009, 21, 386-406.	1.4	47
23	The basis for disease-modifying treatments for Alzheimer's disease: The Sixth Annual Mild Cognitive Impairment Symposium. Alzheimer's and Dementia, 2009, 5, 66-74.	0.4	32
24	Targeting Generation of Antibodies Specific to Conformational Epitopes of Amyloid β -Derived Neurotoxins. CNS and Neurological Disorders - Drug Targets, 2009, 8, 65-81.	0.8	29
25	Antibody Responses, Amyloid β -Peptide Remnants and Clinical Effects of AN-1792 Immunization in Patients with AD in an Interrupted Trial. CNS and Neurological Disorders - Drug Targets, 2009, 8, 88-97.	0.8	37
26	The Pulse of Drug Development for Alzheimers Disease. Reviews on Recent Clinical Trials, 2010, 5, 57-62.	0.4	5
27	Comparison of Intravenous Immunoglobulins for Naturally Occurring Autoantibodies against Amyloid β . Journal of Alzheimer's Disease, 2010, 20, 135-143.	1.2	25
28	Current therapeutic targets for the treatment of Alzheimer's disease. Expert Review of Neurotherapeutics, 2010, 10, 711-728.	1.4	101
29	Vaccination as a Therapeutic Approach to Alzheimer's Disease. Mount Sinai Journal of Medicine, 2010, 77, 17-31.	1.9	43
30	Current Treatment and Recent Clinical Research in Alzheimer's Disease. Mount Sinai Journal of Medicine, 2010, 77, 3-16.	1.9	68
31	Anti-amyloidogenic Activity of IgGs Contained in Normal Plasma. Journal of Clinical Immunology, 2010, 30, 37-42.	2.0	25
32	Immunological Origin and Functional Properties of Catalytic Autoantibodies to Amyloid β Peptide. Journal of Clinical Immunology, 2010, 30, 43-49.	2.0	28
33	Alzheimer's disease: clinical trials and drug development. Lancet Neurology, The, 2010, 9, 702-716.	4.9	1,033
34	Measurement of anti-beta amyloid antibodies in human blood. Journal of Neuroimmunology, 2010, 227, 167-174.	1.1	47
35	The roles of TNF in brain dysfunction and disease. , 2010, 128, 519-548.		190
37	Designed Short Peptides that Form Amyloid-Like Fibrils in Coassembly with Amyloid β Peptide ($A\beta$) Decrease the Toxicity of $A\beta$ to Neuronal PC12 Cells. ChemBioChem, 2010, 11, 1525-1530.	1.3	10
38	Measurement of anti- $A\beta$ 1-42 antibodies in intravenous immunoglobulin with indirect ELISA: The problem of nonspecific binding. Journal of Neuroscience Methods, 2010, 187, 263-269.	1.3	34
39	An $A\beta$ concatemer with altered aggregation propensities. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2010, 1804, 2025-2035.	1.1	1

#	ARTICLE	IF	CITATIONS
40	Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid β peptide elimination from the brain. <i>Journal of Neurochemistry</i> , 2010, 115, 1077-1089.	2.1	212
41	Can we face the challenge of expanding use of intravenous immunoglobulin in neurology?. <i>Acta Neurologica Scandinavica</i> , 2010, 122, 309-15.	1.0	13
42	Specific antibodies to soluble alpha-synuclein conformations in intravenous immunoglobulin preparations. <i>Clinical and Experimental Immunology</i> , 2010, 161, 527-535.	1.1	21
43	Protein aggregation diseases: pathogenicity and therapeutic perspectives. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 237-248.	21.5	639
44	Amyloid- β ; Immunotherapy for Alzheimer's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2010, 9, 197-206.	0.8	80
45	Serum-Derived Immunoglobulins Neutralize Adverse Effects of Amyloid- β Peptide on the Integrity of a Blood-Brain Barrier In Vitro Model. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 303-314.	1.2	9
46	Inherent Anti-amyloidogenic Activity of Human Immunoglobulin γ Heavy Chains. <i>Journal of Biological Chemistry</i> , 2010, 285, 1066-1074.	1.6	18
47	Bapineuzumab: anti- β -amyloid monoclonal antibodies for the treatment of Alzheimer's disease. <i>Immunotherapy</i> , 2010, 2, 767-782.	1.0	52
48	Beneficial Catalytic Immunity to β Peptide. <i>Rejuvenation Research</i> , 2010, 13, 179-187.	0.9	17
49	Antibody Therapy in Neurodegenerative Disease. <i>Reviews in the Neurosciences</i> , 2010, 21, 273-87.	1.4	21
50	Towards Disease-Modifying Treatment of Alzheimer's Disease: Drugs Targeting β -Amyloid. <i>Current Alzheimer Research</i> , 2010, 7, 40-55.	0.7	109
51	Accessing the human repertoire for broadly neutralizing HIV antibodies. <i>MAbs</i> , 2010, 2, 157-164.	2.6	24
52	Antiviral agents in Alzheimer's disease: hope for the future?. <i>Therapeutic Advances in Neurological Disorders</i> , 2010, 3, 141-152.	1.5	43
53	A Meta-Analysis of Cytokines in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2010, 68, 930-941.	0.7	851
54	Human intravenous immunoglobulin provides protection against β toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2010, 7, 90.	3.1	90
55	Intravenous Immunoglobulins as a Treatment for Alzheimer's Disease. <i>Drugs</i> , 2010, 70, 513-528.	4.9	101
56	Can Alzheimer disease be prevented by amyloid- β immunotherapy?. <i>Nature Reviews Neurology</i> , 2010, 6, 108-119.	4.9	329
57	Cholinesterase inhibitor use is associated with increased plasma levels of anti-A β 1-42 antibodies in Alzheimer's disease patients. <i>Neuroscience Letters</i> , 2010, 486, 193-196.	1.0	19

#	ARTICLE	IF	CITATIONS
58	Antibody concentrations to A β 1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations. <i>International Immunopharmacology</i> , 2010, 10, 115-119.	1.7	46
59	Relevance of quantitative measurements of anti-A β antibodies in therapeutic intravenous immunoglobulin using synthetic peptides. <i>International Immunopharmacology</i> , 2010, 10, 373-374.	1.7	0
60	Immunotherapy for Alzheimer's disease. <i>Neuropharmacology</i> , 2010, 59, 303-309.	2.0	26
61	Principles of vaccine design—Lessons from nature. <i>Vaccine</i> , 2010, 28, C14-C24.	1.7	149
62	Targeting A β and tau in Alzheimer's disease, an early interim report. <i>Experimental Neurology</i> , 2010, 223, 252-266.	2.0	80
63	Biological markers of amyloid β -related mechanisms in Alzheimer's disease. <i>Experimental Neurology</i> , 2010, 223, 334-346.	2.0	145
64	Inflammation, Cytokines, Immune Response, Apolipoprotein E, Cholesterol, and Oxidative Stress in Alzheimer Disease: Therapeutic Implications. <i>Rejuvenation Research</i> , 2010, 13, 301-313.	0.9	83
65	Bapineuzumab. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 1121-1130.	1.4	81
66	Antibody-based therapy in Alzheimer's disease. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 343-357.	1.4	56
67	Current and Emerging Drug Treatment Options for Alzheimer's Disease. <i>Drugs</i> , 2011, 71, 2031-2065.	4.9	196
68	Amyloid Clearance as a Treatment Target Against Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 61-73.	1.2	67
69	Principles of Immunopharmacology. , 2011, , .		14
70	C2 Plasma-derived immunoglobulins. , 2011, , 271-301.		1
71	Phagocytic Clearance in Neurodegeneration. <i>American Journal of Pathology</i> , 2011, 178, 1416-1428.	1.9	95
72	Frontiers in Alzheimer's disease therapeutics. <i>Therapeutic Advances in Chronic Disease</i> , 2011, 2, 9-23.	1.1	26
73	Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2011, 25, 997-1019.	2.0	160
75	Chronic Delivery of Antibody Fragments Using Immunoisolated Cell Implants as a Passive Vaccination Tool. <i>PLoS ONE</i> , 2011, 6, e18268.	1.1	7
76	Alzheimers Disease: Review of Emerging Treatment Role for Intravenous Immunoglobulins. <i>Journal of Central Nervous System Disease</i> , 2011, 3, JCNSD.S5018.	0.7	9

#	ARTICLE	IF	CITATIONS
77	Future Targeted Disease Modifying Drugs for Alzheimer's Disease. Recent Patents on CNS Drug Discovery, 2011, 6, 65-76.	0.9	1
78	Alzheimer's disease vaccines: promises and pitfalls. Clinical Investigation, 2011, 1, 969-988.	0.0	2
79	Pharmacological Treatment of Alzheimer Disease. Canadian Journal of Psychiatry, 2011, 56, 579-588.	0.9	96
80	Caffeine Synergizes with Another Coffee Component to Increase Plasma GCSF: Linkage to Cognitive Benefits in Alzheimer's Mice. Journal of Alzheimer's Disease, 2011, 25, 323-335.	1.2	66
81	Therapeutic applications of antibodies in non-infectious neurodegenerative diseases. New Biotechnology, 2011, 28, 511-517.	2.4	7
82	Inflammation and gliosis in neurological diseases – clinical implications. Journal of Neuroimmunology, 2011, 231, 78-85.	1.1	78
83	Strategies for enhancing antibody delivery to the brain. Biochimica Et Biophysica Acta: Reviews on Cancer, 2011, 1816, 191-198.	3.3	23
85	ELISA measurement of specific non-antigen-bound antibodies to A β 1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjects. Journal of Neuroinflammation, 2011, 8, 93.	3.1	22
86	Therapeutic potential of vaccines for Alzheimer's disease. Immunotherapy, 2011, 3, 287-298.	1.0	15
87	Anti- β -Amyloid Immunotherapy for Alzheimers Disease: Focus on Bapineuzumab. Current Alzheimer Research, 2011, 8, 808-817.	0.7	51
88	Naturally Occurring Autoantibodies against β -Amyloid: Investigating Their Role in Transgenic Animal and <i>In Vitro</i> Models of Alzheimer's Disease. Journal of Neuroscience, 2011, 31, 5847-5854.	1.7	111
89	Is targeting beta-amyloid pathology, with immunotherapy, an effective treatment option for Alzheimer's disease?. Reviews in Clinical Gerontology, 2011, 21, 340-345.	0.5	1
90	Human Anti-prion Antibodies Block Prion Peptide Fibril Formation and Neurotoxicity. Journal of Biological Chemistry, 2012, 287, 12858-12866.	1.6	24
91	Immunotherapy for Alzheimer's disease: from anti- β -amyloid to tau-based immunization strategies. Immunotherapy, 2012, 4, 213-238.	1.0	121
92	Strategies, Development, and Pitfalls of Therapeutic Options for Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 28, 241-281.	1.2	51
94	Translational Research in Neurology. Archives of Neurology, 2012, 69, 969-77.	4.9	13
95	Amyloid and Alzheimer's Disease: Inside and Out. Canadian Journal of Neurological Sciences, 2012, 39, 286-298.	0.3	56
96	Naturally Occurring Autoantibodies Against β -Amyloid. Advances in Experimental Medicine and Biology, 2012, 750, 91-99.	0.8	29

#	ARTICLE	IF	CITATIONS
97	Systemic and Central Immunity in Alzheimer's Disease: Therapeutic Implications. <i>CNS Neuroscience and Therapeutics</i> , 2012, 18, 64-76.	1.9	32
98	Safety, tolerability, and antibody response of active A β immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. <i>Lancet Neurology</i> , 2012, 11, 597-604.	4.9	261
99	Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: Quantitative assessment of inflammation and A β amyloid in the muscle. <i>Arthritis and Rheumatism</i> , 2012, 64, 4094-4103.	6.7	25
100	Immunotherapy for Alzheimer's disease. <i>Acta Biochimica Et Biophysica Sinica</i> , 2012, 44, 807-814.	0.9	8
101	Intravenous immunoglobulin protects neurons against amyloid beta peptide toxicity and ischemic stroke by attenuating multiple cell death pathways. <i>Journal of Neurochemistry</i> , 2012, 122, 321-332.	2.1	40
102	Inhibition of Amyloid Formation. <i>Journal of Molecular Biology</i> , 2012, 421, 441-465.	2.0	238
103	Plasma amyloid- β oligomers level is a biomarker for Alzheimer's disease diagnosis. <i>Biochemical and Biophysical Research Communications</i> , 2012, 423, 697-702.	1.0	53
104	Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2012, 9, 105.	3.1	38
105	Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's disease. <i>Journal of Neuroinflammation</i> , 2012, 9, 234.	3.1	13
106	Active DNA A β 42 vaccination as immunotherapy for Alzheimer disease. <i>Translational Neuroscience</i> , 2012, 3, 307-313.	0.7	20
107	Multiple Sclerosis, Alzheimer's Disease, and Inflammation: A Hypothetical View. <i>Molecular and Integrative Toxicology</i> , 2012, , 215-252.	0.5	0
108	Solanezumab for the treatment of mild-to-moderate Alzheimer's disease. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 135-149.	1.3	79
109	Effects of intravenous immunoglobulin on alpha synuclein aggregation and neurotoxicity. <i>International Immunopharmacology</i> , 2012, 14, 550-557.	1.7	12
110	Interaction between intravenous immunoglobulin (IVIg) and the low-density lipoprotein receptor-related protein 1: A role for transcytosis across the blood brain barrier?. <i>Journal of Neuroimmunology</i> , 2012, 251, 39-44.	1.1	10
112	New and emerging treatments for Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 535-543.	1.4	50
113	Immunotoxicity, Immune Dysfunction, and Chronic Disease. <i>Molecular and Integrative Toxicology</i> , 2012, , .	0.5	4
114	Neurovascular Dysfunction and Faulty Amyloid β -Peptide Clearance in Alzheimer Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a011452-a011452.	2.9	207
115	Overview of Mouse Models for Psychiatric and Neurologic Disorders. , 2012, , 738-751.		0

#	ARTICLE	IF	CITATIONS
116	Optimizing diagnosis and management in mild-to-moderate Alzheimer's disease. <i>Neurodegenerative Disease Management</i> , 2012, 2, 291-304.	1.2	9
117	Antigen-Bound and Free β -Amyloid Autoantibodies in Serum of Healthy Adults. <i>PLoS ONE</i> , 2012, 7, e44516.	1.1	9
118	Human Anti- β IgGs Target Conformational Epitopes on Synthetic Dimer Assemblies and the AD Brain-Derived Peptide. <i>PLoS ONE</i> , 2012, 7, e50317.	1.1	13
119	Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review. <i>International Journal of Alzheimer's Disease</i> , 2012, 2012, 1-11.	1.1	241
120	Targeting Beta Amyloid: A Clinical Review of Immunotherapeutic Approaches in Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , 2012, 2012, 1-14.	1.1	66
121	4.5 Literatur. , 2012, , .		0
122	Affinity Chromatography for Purification of IgG from Human Plasma. , 0, , .		1
123	Longitudinal analysis of novel Alzheimer's disease proteomic cerebrospinal fluid biomarkers during intravenous immunoglobulin therapy. <i>Electrophoresis</i> , 2012, 33, 1975-1979.	1.3	13
124	New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 504-517.	1.1	253
125	New and emerging treatments for Alzheimer's disease. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 147-156.	1.0	25
126	Novel roles for the IgG Fc glycan. <i>Annals of the New York Academy of Sciences</i> , 2012, 1253, 170-180.	1.8	160
127	Pathogenic and physiological autoantibodies in the central nervous system. <i>Immunological Reviews</i> , 2012, 248, 68-86.	2.8	36
128	Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors. , 2012, 134, 8-25.		180
129	Intravenous immunoglobulin and Alzheimer's disease: what now?. <i>Journal of Neuroinflammation</i> , 2013, 10, 70.	3.1	44
130	Mechanisms of action of naturally occurring antibodies against β -amyloid on microglia. <i>Journal of Neuroinflammation</i> , 2013, 10, 5.	3.1	25
131	Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?. <i>Immunity and Ageing</i> , 2013, 10, 18.	1.8	97
132	Anti- β antibodies induced by β -Hbc virus-like particles prevent β aggregation and protect PC12 cells against toxicity of β 40. <i>Journal of Neuroscience Methods</i> , 2013, 218, 48-54.	1.3	13
133	Immunity and Alzheimer's disease: immunological perspectives on the development of novel therapies. <i>Drug Discovery Today</i> , 2013, 18, 1212-1220.	3.2	39

#	ARTICLE	IF	CITATIONS
134	Improving Alzheimer's disease phase II clinical trials. , 2013, 9, 39-49.		27
135	Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?. Expert Opinion on Biological Therapy, 2013, 13, 1515-1522.	1.4	20
136	Immunotherapy in prion disease. Nature Reviews Neurology, 2013, 9, 98-105.	4.9	41
137	Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs. Journal of Alzheimer's Disease, 2013, 34, 1-114.	1.2	23
138	A complex dietary supplement augments spatial learning, brain mass, and mitochondrial electron transport chain activity in aging mice. Age, 2013, 35, 23-33.	3.0	19
139	Intravenous immunoglobulin reduces beta amyloid and abnormal tau formation caused by herpes simplex virus type 1. Journal of Neuroimmunology, 2013, 257, 7-12.	1.1	22
140	Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurology, The, 2013, 12, 233-243.	4.9	177
141	Comparison of ELISA measurements of anti-A β concentrations and percentages of specific binding to A β between unfractionated intravenous immunoglobulin products and their purified anti-A β antibodies. Immunology Letters, 2013, 154, 7-11.	1.1	8
142	Alzheimer's disease and Down's syndrome: Treating two paths to dementia. Autoimmunity Reviews, 2013, 12, 670-673.	2.5	20
143	Brain Bioavailability of Human Intravenous Immunoglobulin and its Transport through the Murine Bloodâ€‘Brain Barrier. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 1983-1992.	2.4	139
144	Transgenic expression of β 21 antibody in brain neurons impairs age-dependent amyloid deposition in APP23 mice. Neurobiology of Aging, 2013, 34, 2866-2878.	1.5	4
145	Intravenous immunoglobulin for Alzheimer's disease. Lancet Neurology, The, 2013, 12, 218-219.	4.9	6
146	Intravenous immunoglobulin products contain specific antibodies to recombinant human tau protein. International Immunopharmacology, 2013, 16, 424-428.	1.7	26
147	Toward the Treatment and Prevention of Alzheimer's Disease: Rational Strategies and Recent Progress. Annual Review of Medicine, 2013, 64, 367-383.	5.0	89
148	Immunotherapy against amyloid pathology in Alzheimer's disease. Journal of the Neurological Sciences, 2013, 333, 50-54.	0.3	38
149	A Review: Treatment of Alzheimer's Disease Discovered in Repurposed Agents. Dementia and Geriatric Cognitive Disorders, 2013, 35, 1-22.	0.7	71
150	Immunogenic properties of amyloid beta oligomers. Journal of Biomedical Science, 2013, 20, 10.	2.6	12
151	Immunotherapy for Alzheimer's Disease. Neurologic Clinics, 2013, 31, 869-878.	0.8	20

#	ARTICLE	IF	CITATIONS
152	Prevention of Cognitive Decline. , 2013, , 167-192.		0
153	Immunotherapy for the treatment of Alzheimer's disease: amyloid's; or tau, which is the right target?. ImmunoTargets and Therapy, 2014, 3, 19.	2.7	11
154	Intracranial Injection of Gammagard, a Human IVIg, Modulates the Inflammatory Response of the Brain and Lowers A β in APP/PS1 Mice Along a Different Time Course than Anti-A β Antibodies. Journal of Neuroscience, 2013, 33, 9684-9692.	1.7	65
155	Naturally occurring autoantibodies interfere with β -amyloid metabolism and improve cognition in a transgenic mouse model of Alzheimer's disease 24–h after single treatment. Translational Psychiatry, 2013, 3, e236-e236.	2.4	31
156	A Lipoprotein Receptor Cluster IV Mutant Preferentially Binds Amyloid- β and Regulates Its Clearance from the Mouse Brain. Journal of Biological Chemistry, 2013, 288, 15154-15166.	1.6	33
157	Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer's disease. ImmunoTargets and Therapy, 2013, 2013, 105.	2.7	32
158	Tau Passive Immunotherapy in Mutant P301L Mice: Antibody Affinity versus Specificity. PLoS ONE, 2013, 8, e62402.	1.1	124
159	Intravenous Immunglobulin Binds Beta Amyloid and Modifies Its Aggregation, Neurotoxicity and Microglial Phagocytosis In Vitro. PLoS ONE, 2013, 8, e63162.	1.1	10
160	Evidence for Prion-Like Mechanisms in Several Neurodegenerative Diseases: Potential Implications for Immunotherapy. Clinical and Developmental Immunology, 2013, 2013, 1-20.	3.3	30
161	Emerging Therapeutic Strategies in Alzheimer's Disease. , 0, , .		1
163	Intravenous immunoglobulin for the treatment of Alzheimer's disease: current evidence and considerations. Degenerative Neurological and Neuromuscular Disease, 2014, 4, 121.	0.7	1
164	Pan-Amyloid Oligomer Specific scFv Antibody Attenuates Memory Deficits and Brain Amyloid Burden in Mice with Alzheimer's Disease. Current Alzheimer Research, 2014, 11, 69-78.	0.7	22
165	Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies. Korean Journal of Physiology and Pharmacology, 2014, 18, 447.	0.6	13
166	Alzheimer's Disease and Stem Cell Therapy. Experimental Neurobiology, 2014, 23, 45-52.	0.7	58
167	Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-Modifying Drugs. Update 2014. Journal of Alzheimer's Disease, 2014, 42, 1079-1149.	1.2	5
168	Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered?. Journal of Neuroinflammation, 2014, 11, 198.	3.1	8
169	Intravenous immunoglobulin for Alzheimer's disease. Clinical and Experimental Immunology, 2014, 178, 27-29.	1.1	13
170	How plausible is a link between HSV-1 infection and Alzheimer's disease?. Expert Review of Anti-Infective Therapy, 2014, 12, 275-278.	2.0	24

#	ARTICLE	IF	CITATIONS
171	Amyloid- β concentration and structure influences the transport and immunomodulatory effects of IVIG. <i>Journal of Neurochemistry</i> , 2014, 130, 136-144.	2.1	3
172	Longitudinal effects of intravenous immunoglobulin on Alzheimer's cerebrospinal fluid proteome. <i>Electrophoresis</i> , 2014, 35, 1821-1827.	1.3	3
173	Safety and tolerability of immune globulin intravenous (human), 10% solution in Japanese subjects with mild to moderate Alzheimer's disease. <i>Psychogeriatrics</i> , 2014, 14, 165-174.	0.6	7
174	Amyloid- β -directed immunotherapy for Alzheimer's disease. <i>Journal of Internal Medicine</i> , 2014, 275, 284-295.	2.7	129
175	Evaluating the Murine Anti-Human Antibody Response and Assessment of General Activity and Cognition after Treatment with Human Intravenous Immunoglobulins in Healthy Adult C57/B6 Mice. <i>European Journal of Inflammation</i> , 2014, 12, 489-497.	0.2	4
176	The role of choroid plexus in IVIG-induced beta-amyloid clearance. <i>Neuroscience</i> , 2014, 270, 168-176.	1.1	18
177	Therapeutics of Alzheimer's disease: Past, present and future. <i>Neuropharmacology</i> , 2014, 76, 27-50.	2.0	601
178	Biomarkers in Amyloid- β Immunotherapy Trials in Alzheimer's Disease. <i>Neuropsychopharmacology</i> , 2014, 39, 189-201.	2.8	66
179	Immunotherapy for Alzheimer's disease. <i>Biochemical Pharmacology</i> , 2014, 88, 499-507.	2.0	90
180	Emerging Therapeutics for Alzheimer's Disease. <i>Annual Review of Pharmacology and Toxicology</i> , 2014, 54, 381-405.	4.2	76
181	Intravenous immunoglobulin G improves neurobehavioral and histological outcomes after traumatic brain injury in mice. <i>Journal of Neuroimmunology</i> , 2014, 276, 112-118.	1.1	17
182	Amyloid- β Peptide-specific DARPins as a Novel Class of Potential Therapeutics for Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2014, 289, 27080-27089.	1.6	17
183	Interpreting Alzheimer's disease clinical trials in light of the effects on amyloid- β . <i>Alzheimer's Research and Therapy</i> , 2014, 6, 14.	3.0	30
184	Intravenous Immunoglobulin (IVIG) Treatment Exerts Antioxidant and Neuropreservatory Effects in Preclinical Models of Alzheimer's Disease. <i>Journal of Clinical Immunology</i> , 2014, 34, 80-85.	2.0	21
185	Immunomodulation and AD "Down But Not Out". <i>Journal of Clinical Immunology</i> , 2014, 34, 70-73.	2.0	11
186	Clinical Trials of Intravenous Immunoglobulin for Alzheimer's Disease. <i>Journal of Clinical Immunology</i> , 2014, 34, 74-79.	2.0	62
187	IVIg protects the 3xTg-AD mouse model of Alzheimer's disease from memory deficit and $A\beta$ pathology. <i>Journal of Neuroinflammation</i> , 2014, 11, 54.	3.1	67
188	A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. <i>Annals of Neurology</i> , 2014, 76, 185-205.	2.8	232

#	ARTICLE	IF	CITATIONS
189	Specific binding of intravenous immunoglobulin products to tau peptide fragments. <i>International Immunopharmacology</i> , 2014, 21, 279-282.	1.7	11
190	Herpes Simplex Virus Type 1 and Other Pathogens are Key Causative Factors in Sporadic Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 319-353.	1.2	202
191	Increased Number of Plasma B Cells Producing Autoantibodies Against A β 42 Protofibrils in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 63-72.	1.2	66
192	Anti-A β Oligomer IgG and Surface Sialic Acid in Intravenous Immunoglobulin: Measurement and Correlation with Clinical Outcomes in Alzheimer's Disease Treatment. <i>PLoS ONE</i> , 2015, 10, e0120420.	1.1	12
193	Stress Granules Modulate SYK to Cause Microglial Cell Dysfunction in Alzheimer's Disease. <i>EBioMedicine</i> , 2015, 2, 1785-1798.	2.7	42
194	Imaging neuroinflammation in Alzheimer's disease and other dementias: Recent advances and future directions. <i>Alzheimer's and Dementia</i> , 2015, 11, 1110-1120.	0.4	66
195	Kinetic analysis of IgG antibodies to beta-amyloid oligomers with surface plasmon resonance. <i>Analytical Biochemistry</i> , 2015, 481, 43-54.	1.1	11
196	Identification of target antigens of naturally occurring autoantibodies in cerebrospinal fluid. <i>Journal of Proteomics</i> , 2015, 128, 450-457.	1.2	12
197	Long-term treatment with active A β immunotherapy with CAD106 in mild Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 23.	3.0	112
198	Immunotherapeutic Approaches for Alzheimer's Disease. <i>Neuron</i> , 2015, 85, 1162-1176.	3.8	241
199	The Expanding Role of Therapeutic Antibodies. <i>International Reviews of Immunology</i> , 2015, 34, 202-264.	1.5	22
200	Human Apolipoprotein E μ 4 Expression Impairs Cerebral Vascularization and Blood-Brain Barrier Function in Mice. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 86-94.	2.4	125
201	Strategies for the Prevention of Central Nervous System Complications in Patients with Langerhans Cell Histiocytosis. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 875-893.	0.9	15
202	A β -anti-idiotypic antibodies are present in intravenous immunoglobulin and are produced in mice following its administration. <i>Autoimmunity</i> , 2015, 48, 196-200.	1.2	3
203	A Human Monoclonal IgG That Binds A β Assemblies and Diverse Amyloids Exhibits Anti-Amyloid Activities <i>In Vitro</i> and <i>In Vivo</i> . <i>Journal of Neuroscience</i> , 2015, 35, 6265-6276.	1.7	23
204	Aging Mechanisms. , 2015, , .		4
205	Age-associated evolution of plasmatic amyloid in mouse lemur primates: relationship with intracellular amyloid deposition. <i>Neurobiology of Aging</i> , 2015, 36, 149-156.	1.5	15
206	The effects of intravenous immunoglobulin on cerebral ischemia in rats. <i>Toxicology and Industrial Health</i> , 2016, 32, 229-234.	0.6	6

#	ARTICLE	IF	CITATIONS
207	Tratamiento de la enfermedad de Alzheimer mediante terapia combinada de aféresis terapéutica y hemoféresis con albúmina e inmunoglobulina intravenosa: fundamentos y aproximación terapéutica al estudio AMBAR (Alzheimer Management By Albumin Replacement). <i>Neurología</i> , 2016, 31, 473-481.	0.3	36
208	Probabilistic Cost-Effectiveness Analysis of Vaccination for Mild or Moderate Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2016, 13, 809-816.	0.7	5
209	Current Research Therapeutic Strategies for Alzheimer's Disease Treatment. <i>Neural Plasticity</i> , 2016, 2016, 1-15.	1.0	200
210	Genomics of Alzheimer Disease. <i>JAMA Neurology</i> , 2016, 73, 867.	4.5	105
211	Effective anti-Alzheimer A β therapy involves depletion of specific A β oligomer subtypes. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2016, 3, e237.	3.1	39
212	Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2016, 2, 131-139.	1.8	3
213	Protein aggregation and neurodegenerative diseases: From theory to therapy. <i>European Journal of Medicinal Chemistry</i> , 2016, 124, 1105-1120.	2.6	120
214	Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: Rationale and treatment approach of the AMBAR (Alzheimer Management By Albumin Replacement) study. <i>Neurología (English Edition)</i> , 2016, 31, 473-481.	0.2	18
215	Anti-Amyloid- β Immunotherapy for Alzheimer's Disease. , 2016, , 193-226.		9
216	Blood-Brain Barrier Transport of Alzheimer's Amyloid β -Peptide. , 2016, , 251-270.		5
218	Effects of an amyloid-beta 1-42 oligomers antibody screened from a phage display library in APP/PS1 transgenic mice. <i>Brain Research</i> , 2016, 1635, 169-179.	1.1	15
219	Alzheimer's disease: An overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of natural products. <i>Journal of the Neurological Sciences</i> , 2016, 361, 256-271.	0.3	107
220	Opportunities and challenges in developing relevant animal models for Alzheimer's disease. <i>Ageing Research Reviews</i> , 2016, 26, 112-114.	5.0	40
221	IVIg treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 106-112.	0.9	51
222	Analysis of recent failures of disease modifying therapies in Alzheimer's disease suggesting a new methodology for future studies. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 7-16.	1.4	41
223	Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends. <i>Medicinal Research Reviews</i> , 2017, 37, 1186-1225.	5.0	248
224	Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy. <i>Human Antibodies</i> , 2017, 25, 131-146.	0.6	14
225	Concentrations of antibodies against β -amyloid 40/42 monomer and oligomers in Chinese intravenous immunoglobulins. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 138, 277-282.	1.4	5

#	ARTICLE	IF	CITATIONS
226	Association between naturally occurring anti-amyloid β autoantibodies and medial temporal lobe atrophy in Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 126-131.	0.9	12
227	Antibody blood-brain barrier efflux is modulated by glycan modification. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017, 1861, 2228-2239.	1.1	17
228	Guideline Watch (October 2014): Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. <i>Focus (American Psychiatric Publishing)</i> , 2017, 15, 110-128.	0.4	25
229	A phase 3 trial of IV immunoglobulin for Alzheimer disease. <i>Neurology</i> , 2017, 88, 1768-1775.	1.5	136
230	Update on the use of immunoglobulin in human disease: A review of evidence. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, S1-S46.	1.5	454
231	Lessons from Anti-Amyloid- β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target. <i>Neurodegenerative Diseases</i> , 2017, 17, 242-250.	0.8	34
232	Vaccination strategies in tauopathies and synucleinopathies. <i>Journal of Neurochemistry</i> , 2017, 143, 467-488.	2.1	30
233	Efficacy and safety of anti-amyloid β immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 931-942.	1.7	69
234	Immunotherapy for the Treatment of Alzheimer's Disease. , 2017, , 331-359.		0
235	Una revisi3n de los avances en la terap4utica de la enfermedad de Alzheimer: estrategia frente a la prote5na β -amiloide. <i>Neurolog5a</i> , 2018, 33, 47-58.	0.3	70
236	Review of the advances in treatment for Alzheimer disease: strategies for combating β -amyloid protein. <i>Neurolog5a (English Edition)</i> , 2018, 33, 47-58.	0.2	46
237	Blood Markers in Healthy-Aged Nonagenarians: A Combination of High Telomere Length and Low Amyloid β Are Strongly Associated With Healthy Aging in the Oldest Old. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 380.	1.7	2
238	Intradermal active full-length DNA A β 42 immunization via electroporation leads to high anti-A β antibody levels in wild-type mice. <i>Journal of Neuroimmunology</i> , 2018, 322, 15-25.	1.1	5
239	Intravenous immunoglobulins for Alzheimer's disease and mild cognitive impairment due to Alzheimer's disease: A systematic review with meta-analysis. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 475-480.	1.4	10
240	Anti-A β Antibodies and Cerebral Amyloid Angiopathy Complications. <i>Frontiers in Immunology</i> , 2019, 10, 1534.	2.2	25
242	Serum albumin/globulin ratio is associated with cognitive function in community-dwelling older people: The Septuagenarians, Octogenarians, Nonagenarians Investigation with Centenarians study. <i>Geriatrics and Gerontology International</i> , 2019, 19, 967-971.	0.7	20
243	Assessing Neuroprotective Agents for A β -Induced Neurotoxicity. <i>Trends in Molecular Medicine</i> , 2019, 25, 685-695.	3.5	18
244	Plasma-Based Strategies for Therapeutic Modulation of Brain Aging. <i>Neurotherapeutics</i> , 2019, 16, 675-684.	2.1	11

#	ARTICLE	IF	CITATIONS
246	Intravenous Immunoglobulin for Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2019, 34, 281-289.	0.9	10
247	The de-Alzheimerization of age-related dementias: implications for drug targets and approaches to effective therapeutics. <i>Current Opinion in Pharmacology</i> , 2019, 44, 62-75.	1.7	8
248	Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 61-69.	1.8	63
249	Combination Drug Therapy for the Management of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3272.	1.8	110
250	Amyloid- β , tau, and the cholinergic system in Alzheimer's disease: seeking direction in a tangle of clues. <i>Reviews in the Neurosciences</i> , 2020, 31, 391-413.	1.4	56
251	Immunotherapy for Alzheimer's Disease: Current Scenario and Future Perspectives. <i>Journal of prevention of Alzheimer's disease, The</i> , 2021, 8, 1-18.	1.5	10
252	Five-year outcomes after IVIG for mild cognitive impairment due to Alzheimer disease. <i>BMC Neuroscience</i> , 2021, 22, 49.	0.8	2
254	An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated A β oligomers. <i>Journal of Clinical Investigation</i> , 2012, 122, 1339-1353.	3.9	697
255	Prion Peptide Uptake in Microglial Cells – The Effect of Naturally Occurring Autoantibodies against Prion Protein. <i>PLoS ONE</i> , 2013, 8, e67743.	1.1	15
256	Increased Levels of Antigen-Bound β -Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimer's Disease Patients. <i>PLoS ONE</i> , 2013, 8, e68996.	1.1	45
257	IgG Conformer's Binding to Amyloidogenic Aggregates. <i>PLoS ONE</i> , 2015, 10, e0137344.	1.1	5
258	A β levels in the jugular vein and high molecular weight A β oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer's disease. <i>PLoS ONE</i> , 2017, 12, e0174630.	1.1	8
259	Current Trends in the Development of Drugs for the Treatment of Alzheimer's Disease and their Clinical Trials. <i>Biomedical Chemistry Research and Methods</i> , 2018, 1, e00015.	0.1	7
260	Intravenous Immunoglobulin Reduces Tau Pathology and Preserves Neuroplastic Gene Expression in the 3xTg Mouse Model of Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2014, 11, 655-663.	0.7	14
261	Transport Mechanisms at the Blood-Cerebrospinal-Fluid Barrier: Role of Megalin (LRP2). <i>Recent Patents on Endocrine, Metabolic & Immune Drug Discovery</i> , 2010, 4, 190-205.	0.7	11
262	Alzheimer's Disease and Its Potential Alternative Therapeutics. , 2019, 9, .		12
263	Autoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implications. <i>Journal of Biomedical Research</i> , 2016, 30, 361.	0.7	68
264	Past, present and future of therapeutic strategies against amyloid- β peptides in Alzheimer's disease: a systematic review. <i>Ageing Research Reviews</i> , 2021, 72, 101496.	5.0	131

#	ARTICLE	IF	CITATIONS
265	Therapeutics of Alzheimer's Disease. , 0, , .		1
266	Can VEGF-B Be Used to Treat Neurodegenerative Diseases?. , 0, , .		0
267	The Current Status of Alzheimer's Disease Treatment. <i>Frontiers in Neuroscience</i> , 2012, , 117-161.	0.0	0
268	Modern approach in the therapy of Alzheimer's disease. <i>Učenyje Zapiski Sankt-Peterburgskogo Gosudarstvennogo Medicinskogo Universiteta Im Akad I P Pavlova</i> , 2014, 21, 6-10.	0.0	0
269	Immunotherapeutic Approaches Against Amyloid- β in Drug Discovery for Alzheimer's Disease. , 2015, , 395-415.		0
270	Effect of Different A β Aggregates as Antigen on the Measure of Naturally Occurring Autoantibodies against Amyloid- β 40/42 in IVIG. <i>Current Alzheimer Research</i> , 2020, 16, 1290-1299.	0.7	1
271	Genomics of Alzheimer's disease. , 2020, , 3-18.		0
275	Novel therapeutics for Alzheimer's disease: an update. <i>Current Opinion in Drug Discovery & Development</i> , 2010, 13, 235-46.	1.9	26
276	Development of antihuman IgG antibodies and hematologic deficits but not clinical abnormalities in C57BL/6 mice after repeated administration of human intravenous immunoglobulin. <i>Comparative Medicine</i> , 2012, 62, 31-6.	0.4	5
277	Advances in the development of vaccines for Alzheimer's disease. <i>Discovery Medicine</i> , 2013, 15, 319-26.	0.5	57
278	Alzheimer's disease and immunotherapy. , 2013, 4, 210-20.		11
279	The demand for polyvalent immunoglobulins in Italy. <i>Blood Transfusion</i> , 2013, 11 Suppl 4, s45-54.	0.3	5
280	Novel immunological approaches for the treatment of Alzheimer's disease. <i>Chinese Journal of Contemporary Neurology and Neurosurgery</i> , 2014, 14, 139-151.	0.0	0
290	Anti-Amyloid- β Immunotherapy: A Leading Novel Avenue for Alzheimer's Disease. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, .	1.1	0
291	Alzheimer's disease failed clinical trials. <i>Life Sciences</i> , 2022, 306, 120861.	2.0	42
292	Combination Therapy for the Treatment of Alzheimer's Disease: Recent Progress and Future Prospects. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, 1849-1867.	1.0	3